Optimization techniques for the design and development of: Novel drug delivery systems, Part II

Pharmaceutical Technology

Volumn 27, Issue 3, 2003, Pages 102-118

  Kannan, Vinayagam ^a   Kandarapu, Raghupathi ^a   Garg, Sanjay ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COMPOSITION; OPTIMIZATION; RESEARCH;

DRUG DELIVERY;

DRUG PRODUCTS;

DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; NOVEL DRUG DELIVERY SYSTEM; PHARMACEUTICS; REVIEW;

EID: 0041819885     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. R.K. Verma, B. Mishra, and S. Garg, "Osmotically Controlled Oral Drug Delivery Systems," Drug Dev. Ind. Pharm. 26, 695-708 (2000).
2. R.K. Verma, B.M. Krishna, and S. Garg, "Formulation Aspects in the Development of Osmotically Controlled Oral Drug Delivery Systems," J. Control. Rel. 79, 7-27 (2002).
3. S.V. Sastry, I.K. Reddy, and M.A. Khan, "Atenolol Gastrointestinal Therapeutic System: Optimization of Formulation Variables Using Response Surface Methodology," J. Control. Rel. 45, 121-130 (1997).
4. J.L. Jensen et al., "Variables That Affect the Mechanism of Drug Release from Osmotic Pumps Coated with Acrylate-Methacrylate Copolymer Latexes" J. Pharm. Sci. 84 (5), 530-533 (1995).
5. H.R. Chueh, H. Zia, and C.T. Rhodes, "Optimization of Sotalol Floating and Bioadhesive Extended-Release Tablet Formulations," Drug Dev. Ind. Pharm. 21 (15), 1725-1747 (1995).
6. B.N. Singh and K.H. Kim, "Floating Drug Delivery Systems: An Approach to Oral Controlled Drug Delivery via Gastric Retention," J. Control. Rel. 63, 235-259 (2000).
7. R.K. Verma and S. Garg, "Current Status of Drug Delivery Technologies and Future Directions," Pharm. Technol. On-Line 25 (2), 1-14 (2001).
8. A. Menon, W.A. Ritschel, and A. Sakr, "Development and Evaluation of Monolithic Floating Dosage Form for Frusemide," J. Pharm. Sci. 83 (2), 239-245 (1994).
9. P. Dietrich, A. Bauer-Brandl, and R. Schubert, "Influence of Tableting Forces and Lubricant Concentration on the Adhesion Strength in Complex Layer Tablets," Drug Dev. Ind. Pharm. 26 (7), 745-754 (2000).
10. M.P. Danckwerts, "Optimization and Development of a Core-in-Cup Tablet for Modulated Release of Theophylline in Simulated Gastrointestinal Fluids," Drug Dev. Ind. Pharm. 26 (7), 767-772 (2000).
11. V.K. Gupta et al., "A Novel pH and Time-Based Multiunit Potential Colonic Drug Delivery System, Part II. Optimization of Multiple Response Variables," Int. J. Pharm. 213, 93-102 (2001).
12. S.K. Singh et al., "Optimization and Characterization of Controlled-Release Pellets Coated with an Experimental Latex, Part 1: Anionic Drug," Int. J. Pharm. 125, 243-245 (1995).
13. A. Bodea and S.E. Leucuta, "Optimization of Propranolol Hydrochloride Sustained-Release Pellets Using Box-Behnken Design and Desirability Function," Drug Dev. Ind. Pharm. 24 (2), 145-155 (1998).
14. M.C. Gohel and A.F. Amin, "Formulation Design and Optimization of Modified-Release Microspheres of Didofenac Sodium," Drug Dev. Ind. Pharm. 25 (2), 247-251 (1999).
15. X.M. Zeng, G.P. Martin, and C. Marriott, "Albumin Microspheres as a Means of Drug Delivery to the Lung: Analysis of the Effects of Process Variables on Particle Sizes Using Factorial Design Methodology," Int. J. Pharm. 107, 205-210 (1994).
16. 3 Factorial Design and the Desirability Function," Int. J. Pharm. 248, 51-60 (2002).
17. A.D. McLeod et al., "Optimized Synthesis of Polygluteraldehyde Nanopartides Using Central Composite Design," J. Pharm. Sci. 77 (8), 704-710 (1988).
18. L. Oner and M.J. Groves, "Optimization of Conditions for Preparing 2-5 μm-Range Gelatin Microspheres by Using Chilled Dehydration Agents," Pharm. Res. 10 (4), 621-626 (1993).
19. Y.Q. Hu et al., "Preparation and Evaluation of Insulin-Loaded Polylactide Microspheres Using Factorial Design," Drug Dev. Ind. Pharm. 26 (12), 1309-1313 (2000).
20. K. Abu-Izza, L. Garcia-Contreras, and D.R. Lu, "Preparation and Evaluation of Zidovudine-Loaded Sustained-Release Microspheres, Part 2: Optimization of Multiple Response Variables," J. Pharm. Sci. 85 (6), 572-576 (1996).
21. M.F.L. Law and P.B. Desay, "Use of Canonical and Other Analyses for the Optimization of an Extrusion-Spheronisation Process for Indomethacin," Int. J. Pharm. 146, 1-9 (1997).
22. E Zhou et al., "Optimization of the Processing of Matrix Pellets Based on the Combination of Waxes and Starch Using Experimental Design," Drug Dev. Ind. Pharm. 24 (4), 353-358 (1998).
23. E.E. Hassan and A.G. Eshra, "Formulation of Prolonged- Release Lipid Micropellets by Emulsion Congealing: Optimization of Ketoprofen Entrapment and Release," Int. J. Pharm. 121, 149-155 (1995).
24. J.M. Pean et al., "Optimization of HSA and NGF Encapsulation Yields in PLGA Microparticles," Int. J. Pharm. 166, 105-115 (1998).
25. E. Hamed and A. Sakr, "Application of Multiple-Response Optimization Technique to Extended-Release Formulations Design," J. Control. Rel. 73, 329-338 (2001).
26. D. Hutchings, B. Kuzmak, and A. Sakr, "Processing Considerations for an EC Latex-Coating System: Influence of Curing Time and Temperature," Pharm. Res. 11 (10), 1474-1478 (1994).
27. S. Vaithiyalingam and M.A. Khan, "Optimization and Characterization of Controlled-Release Multiparticulate Beads Formulated with a Customized Cellulose Acetate Butyrate Dispersion," Int J. Pharm. 234, 179-193 (2002).
28. R. Abuzarur-Aloul et al., "Critical Dissolution Tests for Oral Systems Based on Stastically Designed Experiments, Part 2: In Vitro Optimization of Screened Variables on ER-Coated Spheres for the Establishment of an In Vitro-In Vivo Correlation," Drug Dev. Ind. Pharm. 24 (3), 203-212 (1998).
29. M.C. Gohel and A.F. Amin, "Formulation Optimization of Controlled-Release Diclofenac Sodium Microsphres Using Factorial Design," J. Control. Rel. 51, 115-122 (1998).
30. M.C. Gohel and A.F. Amin, "Studies in the Preparation of Diclofenac Sodium Microspheres by Emulsion Solvent Evaporation Technique Using Response Surface Analysis," Ind. J. Pharm. Sci. 61 (1), 48-53 (1999).
31. Y.M. Wang et al., "Optimization of the Formulation Design of Chitosan Microspheres Containing Cisplatin," J. Pharm. Sci. 85 (11), 1204-1210 (1996).
32. A.A. Zaghloul et al., "Response Surface Methodology to Obtain Naproxen Controlled-Release Tablets from Its Microspheres with Eudragit L100-55," J. Microencapsul. 18 (5), 651-662 (2001).
33. A. Delgado, C. Evora, and M. Llabres, "Optimization of 7-day Release (In Vitro) from DL-PLA Methadone Microspheres," Int. J. Pharm. 134, 203-211 (1996).
34. M. Farivar et al., "Factorial Design-Based Optimization of the Formulation of Isosorbide-5-mononitrate Microcapsules," J. Microencapsul. 10 (3), 309-317 (1993).
35. S. Vaithyalingam et al., "Artificial Neural Network and Simplex Optimization for Mixing Aqueous-Coated Beads to Obtain Controlled-Release Formulations," Pharm. Technol. 24 (6), 60-72 (2000).
36. P. Dufour et al., "Improvement of a Microencapsulation with Aqueous Core by Factorial Design," J. Microencapsul. 9 (4), 465-468 (1992).
37. R. Panchagnula, "Transdermal Delivery of Drugs," Ind. J. Pharmacol. 29, 140-156 (1997).
38. Y.-Y. Huang et al., "A Strategy to Optimize the Operation Conditions in Iontophoretic Transdermal Delivery of Pilocarpine," Drug Dev. Ind. Pharm. 21 (14), 1631-1648 (1995).
39. K.K. Kandimalla, N. Kanikkannan, and M. Singh, "Optimization of a Vehicle Mixture for the Transdermal Delivery of Melatonin Using Artificial Neural Networks and Response Surface Methodology," J. Control. Rel. 61, 71-82 (1999).
40. J. Takahara et al., "Multi-Objective Simultaneous Optimization Based on Artificial Neural Network in a Ketoprofen Hydrogel Formula Containing o-Ethyl Menthol as a Percutaneous Absorption Enhancer," Int. J. Pharm. 158, 203-210 (1997).
41. K. Takayama et al., "Formula Optimization Based on Artificial Neural Networks in Transdermal Drug Delivery," J. Control. Rel. 62, 161-170 (1999).
42. P.-C. Wu et al., "Simultaneous Optimization Based on Artificial Neural Networks in Ketoprofen Hydrogel Formula Containing o-Ethyl-3-butylcyclohexanol as Percutaneous Absorption Enhancer," J. Pharm. Sci. 90 (8), 1004-1014 (2001).
43. E. Squillante et al., "Optimization of In Vitro Nifedipine Penetration Enhancement through Hairless Mouse Skin," Int. J. Pharm. 169, 143-154 (1998).
44. R. Lipp and G. Heimann, "Statistical Approach to Optimization of Drying Conditions for a Transdermal Delivery System," Drug Dev. Ind. Pharm. 22 (4), 343-348 (1996).
45. M.A. Khan, J. Dib, and I.K. Reddy, "Statistical Optimization of Ketoprofen-Eudragit S100 Coprecipitates to Obtain Controlled-Release Tablets," Drug Dev. Ind. Pharm. 22 (2), 135-141 (1996).
46. M.A. Khan et al., "Controlled-Release Coprecipitates: Formulation Considerations," J. Control. Rel. 37, 131-141 (1995).
47. M.S. Nagersenker and S.D. Garad, "Physical Characterization and Optimization of Dissolution Parameters of Prochlorperazine Maleate Coevaporates," Int. J. Pharm. 160, 251-255 (1998).
48. M.S. Nagersenker, S.D. Garad, and G. Ramprakash, "Design, Optimization, and Evaluation of Domperidone Coevaporates," J. Control. Rel. 63, 31-39 (2000).
49. P. Dangprasit and G.C. Ritthidej, "Development of Diclofenac Sodium Controlled-Release Solid Dispersions by Spray Drying Using Optimization Strategy, Part 1: Powder Formulation," Drug Dev. Ind. Pharm. 21 (20), 2323-2337 (1995).
50. A.A. Karnachi and M.A. Khan, "Box-Behnken Design for the Optimization of Formulation Variables of Indomethacin Coprecipitates with Polymer Mixtures," Int. J. Pharm. 131, 9-17 (1996).
51. R. Barnadas-Rodriguez and M. Sabes, "Factors Involved in the Production of Liposomes with a High-Pressure Homogenizer," Int. J. Pharm. 213, 175-186 (2001).
52. (K-P) Fractional Factorial Design for the Formulation Optimization of Novel Multicomponent Liposomes," J. Pharm. Biomed. Anal. 17, 133-140 (1998).
53. M. Mobed and T.M.S. Chang, "Adsorption of Chitin Derivatives onto Liposomes: Optimization of Adsorption Conditions," J. Microencapsul. 15 (5), 595-607 (1998).
54. S. Bjerregaard et al., "Formulation and Evaluation of Release and Swelling Mechanism of a Water-in-Oil Emulsion Using Factorial Design," Int. J. Pharm. 193, 1-11 (1999).
55. Y. Bi, Y. Yonezawa, and H. Sunada, "Rapidly Disintegrating Tablets Prepared by the Wet Compression Method: Mechanism and Optimization," J. Pharm. Sci. 88 (10), 1004-1010 (1999).
56. B. Rotthauser, G. Kraus, and P.C. Schmidt, "Optimization of an Effervescent Tablet Formulation Containing Spray-Dried L-leucine and Polyethylene Glycol 6000 as Lubricants Using a Central Composite Design," Eur. J. Pharm. Biopharm. 46 (1), 85-94 (1998).
57. M. Kuentz and D. Rothlisberger, "Determination of the Optimal Amount of Water in Liquid-Fill Masses for Hard Gelatin Capsules by Means of Texture Analysis and Experimental Design," Int. J. Pharm. 236, 145-152 (2002).
58. S. Branchu and et al., "A Central Composite Design to Investigate the Thermal Stability of Lysozyme," Pharm. Res. 16 (5), 702-708 (1999).
59. B. Singh and N. Ahuja, "Development of Controlled- Release Buccoadhesive Hydrophilic Matrices of Diltiazem Hydrochloride: Optimization of Bioadhesion, Dissolution, and Diffusion Parameters," Drug Dev. Ind. Pharm. 28 (4), 431-442 (2002).
60. V. Agarwal et al., "Cataplasm-Based Controlled Drug Delivery: Development and Optimization of a Novel Formulation," Drug Dev. Ind. Pharm. 25 (5), 659-655 (1999).
61. S.A. Charman et al., "Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound," Pharm. Res. 9, 87-93 (1992).
62. S. Nazzal et al., "Optimization of a Self-Nanoemulsified Tablet Dosage Form of Ubiquinone Using Response Surface Methodology: Effect of Formulation Ingredients," Int. J. Pharm. 240, 103-114 (2002).
63. T. Durig and R. Fassihi, "Mechanistic Evaluation of Binary Effects of Magnesium Stearate and Talc as Dissolution Retardants at 85% Drug Loading in an Experimental Extended-Release Formulation," J. Pharm. Sci. 86 (10), 1092-1098 (1997).
64. E.E. Hassan, R.C. Perish, and J.M. Gallo, "Optimized Formulation of Magnetic Chitosan Microspheres Containing the Anticancer Agent, Oxantrazole," Pharm. Res. 9 (3), 390-397 (1992).
65. S. Elkheshen,"Simplex Lattice Design for the Optimization of a Water-Soluble Drug Using Poly(lactic acid) and Poly(lactide coglucolide) Copolymer" J. Microencapsul. 13 (4), 447-462 (1996).